Drug Patents owned by Bausch And Lomb

1. List of Besivance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062 BAUSCH AND LOMB Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
Nov, 2029

(6 years from now)

US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Mar, 2030

(7 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection
Nov, 2030

(7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

2. List of Prolensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129431 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927606 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US9561277 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8871813 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US9144609 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8669290 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8754131 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US10085958 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2032

(9 years from now)

US9517220 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2033

(10 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PROLENSA before it's patent expiration?
More Information on Dosage

3. List of Vyzulta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058467 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 10 months from now)

US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 10 months from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(1 year, 10 months from now)

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of VYZULTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic